Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metoclopramide is a small molecule pharmaceutical drug classified as a prokinetic and antiemetic agent. It is primarily used to treat gastroesophageal reflux disease (GERD) that does not respond to other treatments, diabetic gastroparesis (delayed stomach emptying), and for the prevention of nausea and vomiting associated with chemotherapy, surgery, or certain medical procedures. Metoclopramide works by increasing muscle contractions in the upper digestive tract, thereby speeding gastric emptying and improving gastrointestinal motility. Its mechanism of action involves antagonism of dopamine D2 receptors (both centrally in the chemoreceptor trigger zone and peripherally in the gut), agonism at serotonin 5-HT4 receptors, weak antagonism at serotonin 5-HT3 receptors, and enhancement of acetylcholine release via muscarinic receptor modulation. These actions result in increased lower esophageal sphincter tone, accelerated gastric transit, and antiemetic effects[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metoclopramide.